About us
We are a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Bristol Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.
Each day, our employees around the world work together for patients—it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunology, and fibrosis. Through our Research & Development organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.
As global citizens, we work sustainably and responsibly and seek to give back. Through the Bristol Myers Squibb Foundation, we promote health equity and strive to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
Bristol Myers Squibb Singapore
Bristol Myers Squibb is a global biopharmaceutical company that is focused on discovering, developing, and delivering innovative medicines to help patients prevail over serious diseases. It focuses on driving scientific and academic excellence while rigorously developing innovative, high-quality treatments to meet patient needs. The company also works to make its innovations accessible to a broader group of patients by advocating for policies that promote equality, fairness, and inclusion in healthcare. We provide neutral and accurate information about our products.
Visit our website to report adverse reactions caused by the use of the product. Complain about product quality or request medical information of our products.
Global business
Update 2024